Systemic lupus and malignancies

Purpose of reviewIndividuals with systemic lupus erythematosus (SLE) have an increased susceptibility to certain types of cancer. Given concerns focused on this issue, we present a review of this important topic. Recent findingsIn non-Hodgkin lymphoma (NHL), a several-fold increased risk is seen in SLE versus the general population. It has long been suspected that immunosuppressive drugs play a role in this risk, but there may be other important driving factors as well. Lupus disease activity may itself heighten the risk of lymphoma in diseases like SLE. Lung cancer risk also is increased in SLE; smoking appears to drive this risk. Additionally, cervical dysplasia risk is increased in SLE, particularly with immunosuppressive drug exposure. An altered clearance of cancer-related viral agents in SLE (due to the disease and/or immunosuppression) may contribute to this risk and may also drive the risk for other cancers (such as vulvovaginal and hepatic carcinomas) in SLE. On the positive side, one new and significant finding is that SLE patients seem to have a decreased risk of certain nonhematologic cancers (breast, ovarian, endometrial, and prostate). SummaryThough much has been learnt so far regarding the risk in SLE, much yet remains unknown.

[1]  M. Urowitz,et al.  Lung cancer in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.

[2]  C. Gordon,et al.  Prostate cancer in systemic lupus erythematosus , 2011, International journal of cancer.

[3]  I. Lundberg,et al.  Expression of APRIL in Diffuse Large B Cell Lymphomas from Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis , 2011, The Journal of Rheumatology.

[4]  W. Foulkes,et al.  Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis , 2011, British Journal of Cancer.

[5]  M. Santiago,et al.  Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review , 2011, Clinical Rheumatology.

[6]  S. Bae,et al.  Prevalence of Human Papilloma Virus Infections and Cervical Cytological Abnormalities among Korean Women with Systemic Lupus Erythematosus , 2010, Journal of Korean medical science.

[7]  E. Klumb,et al.  Is Higher Prevalence of Cervical Intraepithelial Neoplasia in Women With Lupus Due to Immunosuppression? , 2010, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[8]  M. Wong,et al.  Natural History of Cervical Papilloma Virus Infection in Systemic Lupus Erythematosus — A Prospective Cohort Study , 2010, The Journal of Rheumatology.

[9]  E. Hellström-Lindberg,et al.  Myeloid leukaemia in systemic lupus erythematosus--a nested case-control study based on Swedish registers. , 2009, Rheumatology.

[10]  J. Strobl,et al.  Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells , 2009, Anti-cancer drugs.

[11]  A. Rosenwald,et al.  Molecular pathogenesis of follicular lymphoma , 2008, Haematologica.

[12]  R. Amaravadi.  Autophagy-induced tumor dormancy in ovarian cancer. , 2008, The Journal of clinical investigation.

[13]  Richard H. White,et al.  Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California , 2008, Cancer Causes & Control.

[14]  M. Urowitz,et al.  The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case–cohort study , 2007, Annals of the rheumatic diseases.

[15]  A. Ekbom,et al.  A closer look at non-Hodgkin’s lymphoma cases in a national Swedish systemic lupus erythematosus cohort: a nested case-control study , 2007, Annals of the rheumatic diseases.

[16]  G. Hughes,et al.  High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. , 2007, Arthritis and rheumatism.

[17]  G. Ruiz-Irastorza,et al.  Antimalarials may influence the risk of malignancy in systemic lupus erythematosus , 2007, Annals of the rheumatic diseases.

[18]  L. Pasquier,et al.  Orphanet Journal of Rare Diseases , 2006 .

[19]  M. Urowitz,et al.  Mortality in systemic lupus erythematosus. , 1987, Arthritis and rheumatism.

[20]  C. Pineau,et al.  Cancer screening in patients with systemic lupus erythematosus. , 2006, The Journal of rheumatology.

[21]  D. Gladman,et al.  Non-Hodgkin’s lymphoma in systemic lupus erythematosus , 2005, Annals of the rheumatic diseases.

[22]  D. Gladman,et al.  An international cohort study of cancer in systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[23]  C. Gordon,et al.  Factors associated with abnormal Pap results in systemic lupus erythematosus. , 2004, Rheumatology.

[24]  P. Chan,et al.  Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. , 2004, Arthritis and rheumatism.

[25]  R. Shore,et al.  Aspirin and lung cancer in women , 2002, British Journal of Cancer.

[26]  D. Isenberg,et al.  Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades , 2002, Annals of the rheumatic diseases.

[27]  A. Ekbom,et al.  Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus , 2002, Scandinavian journal of rheumatology.

[28]  Edgar M Moran,et al.  Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[29]  J. Ager,et al.  Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. , 2001, Gynecologic oncology.

[30]  J. Sibley,et al.  Systemic lupus erythematosus and the risk of malignancy , 2001, Lupus.

[31]  M. Peterson,et al.  Increased cervical dysplasia in intravenous cyclophosphamidetreated patients with SLE: a preliminary study , 2000, Lupus.

[32]  H. Howe,et al.  Increased risk of malignancy in patients with systemic lupus erythematosus. , 1998, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[33]  R. Hoover,et al.  Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[34]  A. Zauber,et al.  Incidence of second cancers in patients treated for Hodgkin's disease. , 1995, Journal of the National Cancer Institute.

[35]  Z. Blumenfeld,et al.  Systemic Lupus Erythematosus: Predisposition for Uterine Cervical Dysplasia , 1994, Lupus.

[36]  J. M. Porcel,et al.  Monoclonal Gammopathy in Systemic Lupus Erythematosus , 1992, Lupus.

[37]  E. Pukkala,et al.  Increased risk of cancer in patients with systemic lupus erythematosus. , 1992, Annals of the rheumatic diseases.

[38]  D. Gladman,et al.  Mortality in systemic lupus erythematosus. , 2006, The Journal of rheumatology. Supplement.

[39]  G. Nyberg,et al.  Increased incidence of cervical atypia in women with systemic lupus erythematosus treated with chemotherapy. , 1981, Arthritis and rheumatism.